UNSPSC 51282312: Erythromycin a

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as erythromycin estolate impurity, free erythromycin-, but more generally known as erythromycin a, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules erythromycin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG.

Most nations, for tariff purposes, schedule erythromycin a under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.

UNSPSC 51282312 Erythromycin A, a Commodity code, nominally covers a single antibiotic product, yet recent state and local procurement activity shows little direct purchasing of erythromycin itself. Instead, issuing bodies are sourcing other pharmaceutical products — antibiotics, opioid-reversal agents, and drug-disposal systems — through piggyback contracts and competitive bidding processes that appear to route purchases through broader pharmaceutical supply frameworks. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (both antibiotics in the same therapeutic family), indicating that state health departments are consolidating antibiotic procurement through pre-negotiated vehicles rather than issuing code-specific solicitations. Issuing bodies include state health departments and county health authorities; both use cooperative purchasing agreements and traditional competitive-bid processes to manage pharmaceutical supply chains.

Activity appears concentrated in the South and Midwest, with documented recent procurement from the Illinois Department of Public Health (award posted August 2026) and Seminole County, Florida (IFB posted June 2026 for Naloxone and drug-deactivation systems). The Seminole County opportunity, while unrelated to erythromycin specifically, illustrates the broader pattern: counties and state agencies are using structured competitive processes and FEMA-potentially-funded mechanisms to acquire pharmaceutical products in bulk with quarterly delivery cycles and fixed-fee pricing. No open solicitations directly naming erythromycin appear in recent state and local postings, suggesting that demand for this specific antibiotic may be absorbed through standing framework contracts or that procurement is channeled through piggyback vehicles negotiated at the state or multi-state consortium level rather than through individual commodity-level RFPs or ITBs.